We bring you the latest updates from Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. through a simple and fast subscription.
We can deliver your news in your inbox, on your phone or you can read them here on this website on your personal news page.
Unsubscribe at any time without hassle.
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals.'s title: Diabetes In Control | Expert News, Research & Tools for Better Care
Is this your feed? Claim it!
A patient starts semaglutide through a telehealth platform, receives nutrition advice from a wellness clinic, and later visits a primary care physician for worsening gastrointestinal symptoms. None of the providers can see the full treatment picture. Situations like this are becoming increasingly common as GLP-1 medications move across multiple corners of healthcare.
W...
A patient loses 30 pounds, lowers their A1C, and improves their blood pressure within months of starting a GLP-1 medication. Stories like these are hard to ignore, and they have helped fuel growing enthusiasm around drugs like Ozempic, Wegovy, and Mounjaro. Yet as prescriptions continue to expand beyond high-risk diabetes patients, a difficult question is beginning to surface...
The rapid rise of GLP-1 receptor agonists has transformed diabetes treatment and obesity management over the past decade. However, high prices and limited insurance coverage continue to restrict access for many patients. As patents evolve and global pharmaceutical markets shift, conversations about lower-cost GLP-1 therapies are gaining momentum. Clinicians are now asking an ...
For many patients with obesity-related osteoarthritis, daily movement can feel like walking with a heavy backpack that never comes off. Joint pain limits exercise, reduced activity leads to more weight gain, and the cycle continues. However, new research is raising an important question: could GLP-1 therapies help break that cycle?
Recent trials are exploring how GLP-1...
What if a medication designed to lower blood sugar could also help protect the brain? That question is driving growing interest among researchers studying the connection between GLP-1 drugs and Parkinson’s disease. Scientists are now exploring whether therapies originally developed for type 2 diabetes and obesity may influence inflammation, neuronal survival, and the progress...